Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AstraZeneca stock | 56.29

Own AstraZeneca stock in just a few minutes.

Fact checked

AstraZeneca PLC is a drug manufacturers—general business based in the US. AstraZeneca shares (AZN) are listed on the NASDAQ and all prices are listed in US Dollars. AstraZeneca employs 70,600 staff and has a trailing 12-month revenue of around USD$25.9 billion.

In mid-November, AstraZeneca announced that its COVID-19 vaccine, which was developed in partnership with the University of Oxford, has an average efficacy of 70%. In some clinical tests, the vaccine was 90% effective. The company says it will have 3 billion doses of the vaccine available in 2021.

The company’s vaccine follows news that Moderna and Pfizer have each developed vaccines. Shares of AstraZeneca (AZN) were down following the news.

How to buy shares in AstraZeneca

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AstraZeneca. Find the stock by name or ticker symbol: AZN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AstraZeneca reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$56.29, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AstraZeneca, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AstraZeneca. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AstraZeneca's share price?

Since the stock market crash in March caused by coronavirus, AstraZeneca's share price has had significant positive movement.

Its last market close was USD$56.29, which is 10.87% up on its pre-crash value of USD$50.17 and 55.71% up on the lowest point reached during the March crash when the shares fell as low as USD$36.15.

If you had bought USD$1,000 worth of AstraZeneca shares at the start of February 2020, those shares would have been worth USD$799.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,160.14.

AstraZeneca share price

Use our graph to track the performance of AZN stocks over time.

AstraZeneca shares at a glance

Information last updated 2020-11-24.
Latest market close USD$56.29
52-week range USD$35.8633 - USD$64.425
50-day moving average USD$53.8097
200-day moving average USD$54.5689
Wall St. target price USD$59.73
PE ratio 58.2105
Dividend yield USD$1.4 (2.56%)
Earnings per share (TTM) USD$0.95

Buy AstraZeneca shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AstraZeneca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AstraZeneca price performance over time

Historical closes compared with the close of $56.29 from 2020-11-16

1 week (2020-11-19) 4.18%
1 month (2020-10-26) 6.07%
3 months (2020-08-26) -1.25%
6 months (2020-05-26) 5.99%
1 year (2019-11-26) 15.44%
2 years (2018-11-26) 40.41%
3 years (2017-11-24) 66.34%
5 years (2015-11-25) 65.02%

Is AstraZeneca under- or over-valued?

Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AstraZeneca's P/E ratio

AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 58x. In other words, AstraZeneca shares trade at around 58x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AstraZeneca's PEG ratio

AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2823. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AstraZeneca's EBITDA

AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$7.7 billion.

The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.

AstraZeneca financials

Revenue TTM USD$25.9 billion
Operating margin TTM 19.86%
Gross profit TTM USD$19.5 billion
Return on assets TTM 5.22%
Return on equity TTM 17.71%
Profit margin 9.65%
Book value $4.6475
Market capitalisation USD$139.7 billion

TTM: trailing 12 months

Shorting AstraZeneca shares

There are currently 6.0 million AstraZeneca shares held short by investors – that's known as AstraZeneca's "short interest". This figure is 20.2% up from 5.0 million last month.

There are a few different ways that this level of interest in shorting AstraZeneca shares can be evaluated.

AstraZeneca's "short interest ratio" (SIR)

AstraZeneca's "short interest ratio" (SIR) is the quantity of AstraZeneca shares currently shorted divided by the average quantity of AstraZeneca shares traded daily (recently around 4.2 million). AstraZeneca's SIR currently stands at 1.44. In other words for every 100,000 AstraZeneca shares traded daily on the market, roughly 1440 shares are currently held short.

However AstraZeneca's short interest can also be evaluated against the total number of AstraZeneca shares, or, against the total number of tradable AstraZeneca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AstraZeneca's short interest could be expressed as 0% of the outstanding shares (for every 100,000 AstraZeneca shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable AstraZeneca shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AstraZeneca.

Find out more about how you can short AstraZeneca stock.

AstraZeneca share dividends

73%

Dividend payout ratio: 72.54% of net profits

Recently AstraZeneca has paid out, on average, around 72.54% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.56% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.56% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about $1.4 per share.

AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AstraZeneca's most recent dividend payout was on 14 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 13 August 2020 (the "ex-dividend date").

Have AstraZeneca's shares ever split?

AstraZeneca's shares were split on a 2:1 basis on 27 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca shares which in turn could have impacted AstraZeneca's share price.

AstraZeneca share price volatility

Over the last 12 months, AstraZeneca's shares have ranged in value from as little as $35.8633 up to $64.425. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca's is 0.2994. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).

AstraZeneca overview

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site